Sentences with phrase «funds at these reduced prices»

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The Case for Reduced Funding Levels When you look at the demand shock above you'll notice that there are both higher prices and higher «quantities» of companies and I know many entrepreneurs think this is good.

Often, clone funds secured at a reduced price serve the shareholder investments in clone funds at a lower risk.

That leaves the ETF issuer with shares bought at or above today's market price, thus reducing the fund company's total tax burden even further.

The growing availability of credit has also expanded the resources available to new entrepreneurs launching businesses, and has given many families access to the funds they need to «smooth over» periods of financial challenge.9 / At the same time, competition among lenders for individuals with solid credit histories has reduced the price of credit for those consumers.10 /

Klopfenstein and Thomas (2010) offer three significant ways in which non-AP students at a school may pay the price for the AP program: they may receive lower instructional quality, as the best teachers are siphoned off to teach AP students; they are in larger classes, as AP classes are smaller than typical high school classes; and non-AP course offerings are reduced or limited in order to fund, staff, and expand AP course offerings.

At the same time, Cuomo insisted his own plan to fund the Metropolitan Transportation Authority and reduce vehicle congestion through the congestion pricing plan was «difficult» but more «feasible» to pass the Legislature.

However, in at least some cases, free and reduced - price school meals data have been used for this purpose to allocate funds to some LEAs, including all funds for charter schools that are treated as separate LEAs under state law.

My experience at Capital City — a diverse, open - enrollment, publicly funded school with more than 70 percent of students qualifying for reduced - price meals — has shown me the opposite is true.

Maryland Hunger Solutions strongly supports Maryland Meals for Achievement (MMFA), a state - funded program that expands access to universal, free Breakfast in the Classroom in schools where at least 40 % of students are eligible for free and reduced priced meals.

In 2015 - 16, districts were required to cover only $ 15 of the $ 93 exam fee for students who qualify for free or reduced - price meals thanks in part to the U.S. Department of Education's Advanced Placement Test Fee Grant Program, which provided funding for low - income students to take AP exams at a reduced rate.

By offering their e-books for sale at reduced prices with all of the proceeds going to support various causes, vital funding is given to charitable organizations and much - needed publicity is available to authors.

If the veteran makes a downpayment of at least 5 percent, but less than 10 percent of the purchase price of the property, the funding fee is reduced to 1.50 percent of the loan amount (2.25 percent for reservists).

Investments in securities that are difficult to purchase or sell (illiquid or thinly - traded securities) may reduce returns if the Fund is unable to sell the securities at advantageous times or prices.

That's a good thing and a bad thing: On the plus side, you may have access to lower - cost versions of those specific funds, especially at very large companies that qualify for reduced pricing.

While RGGI didn't induce enough of a price signal to directly reduce emissions at the covered power plants, the activities funded by auction revenue did offer benefits including «emission reduction, consumer savings via lower electricity bills, and job creation,» according to CRS.

BC residents can take our Passive House Design and Construction courses in BC at a reduced price, thanks to generous funding from the Government of BC.

It might lead to looking at system - wide pricing to reduce transaction costs given this shared and common interest among funders in community and public access to this body of knowledge.

The analysis suggests that funding state - based innovation grants at the cost of $ 9 billion could bring the price of the benchmark silver plan down by nearly 25 % and reduce subsidy outlays.